Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Mounjaro · Zepbound · LY3298176
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Dual GIP/GLP-1 agonist peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Single molecule acting at GIP and GLP-1 receptors; not a two-drug stack.
Evidence and critical reading
Reported scientific and empirical uses
Reported glycemic control · Cardiovascular and vascular function · Reported weight management
Authorized products coexist with commercial weight-loss use; the record separates diabetes, obesity and formulations.
Human evidence
SURMOUNT-1 established substantial average weight reduction; individual response varies.
Preclinical evidence
Dual-receptor biology does not validate adding another incretin.
Critical reading and limitations
SURMOUNT-1 supports weight loss in participants without diabetes; it does not show that adding retatrutide improves benefit/risk.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Tirzepatide Once Weekly for the Treatment of Obesity.
5 / 10 / 15 mg · Target amounts in separate randomized arms
- Frequency
- Weekly
- Duration
- 72 weeks with protocolized escalation
- Route
- Subcutaneous
- Context
- SURMOUNT-1; alternative arms, not a self-management sequence.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID35658024 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
US: Mounjaro/Zepbound have distinct approved indications. EU: Mounjaro authorized for diabetes and adult weight management under label conditions.
Adverse effects and unknowns
GI effects and gallbladder/pancreatitis warnings. US MTC/MEN2 and hypersensitivity contraindications. Hypoglycemia risk with insulin/secretagogues; reduced oral contraceptive exposure is label-supported.
GI effects; labeling contains specific warnings and oral-contraception considerations during initiation/dose changes.
Contraindications
US Zepbound: personal/family medullary thyroid carcinoma or MEN2 and serious hypersensitivity.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Insulin/secretagogues: hypoglycemia. Oral hormonal contraceptive efficacy can decrease after initiation/escalation; review the exact label/method.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID35658024 · Randomized controlled trial
Adults without diabetes with obesity/overweight.
Weekly SC, 72 weeks.
15-mg arm: −20.9% versus −3.1% with placebo; other arms differed.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 2539
Trials attributed in the package
NCT04184622 · A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightRegistry status: CompletedLast update posted: July 24, 2025Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Tirzepatide · 300 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07868354 · A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07878494 · Dietary, Medication, and Endoscopic Interventions for Post-Bariatric HypoglycemiaRegistry status: Not yet recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07677865 · GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationRegistry status: WithdrawnLast update posted: October 16, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- EMA-MOU
October 16, 2026
- PMID35658024
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators.
October 16, 2026
- R30
- REG-ZEP
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026